La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Verastem Gestion

Gestion contrôle des critères 0/4

Le PDG Verastem's est Dan Paterson, nommé en Jun2019, a un mandat de 5.17 ans. La rémunération annuelle totale est $ 3.63M, composée du salaire de 15% et des bonus 85%, y compris les actions et options de la société. détient directement 0.095% des actions de la société, d'une valeur de $ 95.20K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.4 ans et 3 ans.

Informations clés

Dan Paterson

Directeur général

US$3.6m

Rémunération totale

Pourcentage du salaire du PDG	15.0%
Durée du mandat du directeur général	5.2yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	1.4yrs
Durée moyenne du mandat des membres du conseil d'administration	3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Dan Paterson a-t-elle évolué par rapport aux bénéfices de Verastem?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	US$4m	US$545k	-US$87m
Sep 30 2023	n/a	n/a	-US$77m
Jun 30 2023	n/a	n/a	-US$75m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$698k	US$470k	-US$74m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$78m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$2m	US$460k	-US$71m
Sep 30 2021	n/a	n/a	-US$75m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$45m
Dec 31 2020	US$2m	US$467k	-US$68m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$130m
Mar 31 2020	n/a	n/a	-US$149m
Dec 31 2019	US$2m	US$445k	-US$149m

Rémunération vs marché: La rémunération totale de Dan ($USD 3.63M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Dan a augmenté alors que l'entreprise n'est pas rentable.

PDG

Dan Paterson (63 yo)

5.2yrs

Titularisation

US$3,626,857

Compensation

Mr. Daniel W. Paterson, also known as Dan, serves as Chief Executive Officer Verastem, Inc. since August 1, 2023 and is its President of Verastem, Inc. since June 2019. He is Director of Verastem, Inc. sin...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Daniel Paterson	President	5.2yrs	US$3.63m	0.095% $ 95.2k
Daniel Calkins	CFO and Principal Accounting & Financial Officer	1.8yrs	US$622.56k	0.016% $ 16.4k
Richard Aldrich	Founder and Consultant	9.9yrs	US$114.77k	pas de données
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	pas de données	pas de données
Piyush Gupta	Co-Founder	no data	pas de données	pas de données
Michelle Dipp	Co-Founder	no data	pas de données	pas de données
Jonathan Pachter	Chief Scientific Officer	8.3yrs	US$319.51k	pas de données
Nate Sanburn	Senior Vice President of Corporate Development & External Engagement	less than a year	pas de données	pas de données
Cathy Carew	Chief Organizational Effectiveness Officer	no data	pas de données	pas de données
Michael Crowther	Chief Commercial & Business Strategy Officer	less than a year	pas de données	pas de données
Colleen Mockbee	Global Head of Regulatory Affairs & Development	less than a year	pas de données	pas de données
John Hayslip	Chief Medical Officer	less than a year	pas de données	pas de données

1.4yrs

Durée moyenne de l'emploi

55.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de VSTM n'est pas considérée comme expérimentée (ancienneté moyenne 1.4 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Daniel Paterson	President	1.1yrs	US$3.63m	0.095% $ 95.2k
Robert Weinberg	Co-Founder & Chair of Scientific Advisory Board	no data	pas de données	pas de données
Mario Sznol	Member of Scientific Advisory Board	no data	pas de données	pas de données
Michael Kauffman	Lead Independent Director	11.8yrs	US$124.29k	0.0014% $ 1.4k
Paul A. Bunn	Independent Director	3.2yrs	US$74.29k	0% $ 0
Eric Rowinsky	Independent Director	7.3yrs	US$89.29k	0% $ 0
John Johnson	Independent Director	4.3yrs	US$81.29k	0% $ 0
Robert Gagnon	Director	1.7yrs	US$64.29k	0.054% $ 53.9k
Channing Der	Member of Scientific Advisory Board	2.4yrs	pas de données	pas de données
Brian Stuglik	Director	6.9yrs	US$2.30m	0.24% $ 241.6k
Anil Kapur	Independent Director	1.8yrs	US$81.75k	0% $ 0
Michelle Robertson	Independent Director	2.8yrs	US$84.29k	0% $ 0

3.0yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de VSTM ne sont pas considérés comme expérimentés (ancienneté moyenne 3 ans), ce qui suggère un nouveau conseil d'administration.

Verastem Gestion

Gestion contrôle des critères 0/4

Informations clés

Mises à jour récentes de la gestion

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Announces Executive Appointments

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Recent updates

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration